Nephros (NEPH) Gains from Sales and Divestitures (2018 - 2025)

Nephros' Gains from Sales and Divestitures history runs 8 years deep, the most recent figure standing at $70708.0 for Q4 2025.

• In Q4 2025, Gains from Sales and Divestitures rose 67.69% year-over-year to $70708.0; the TTM figure through Dec 2025 stood at $70708.0 (up 67.69% YoY), while the FY2025 annual figure was $70708.0, up 67.69% from the prior year.
• Gains from Sales and Divestitures was $70708.0 for Q4 2025 at Nephros, down from $160843.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $187503.0 in Q4 2023 to a low of $23781.0 in Q4 2021.
• Historically, Gains from Sales and Divestitures has averaged $102682.8 across 5 years, with a median of $108161.0 in 2025.
• The sharpest annual moves came in 2021 and 2023: Gains from Sales and Divestitures tumbled 99.96% in 2021, then jumped 319.17% in 2023.
• A 5-year view of Gains from Sales and Divestitures shows it stood at $23781.0 in 2021, then jumped by 88.1% to $44732.0 in 2022, then surged by 319.17% to $187503.0 in 2023, then sank by 77.51% to $42167.0 in 2024, then soared by 67.69% to $70708.0 in 2025.
• The last three Gains from Sales and Divestitures figures came in at $70708.0 (Q4 2025), $160843.0 (Q3 2025), and $146114.0 (Q2 2025), per Business Quant data.